Clinical manifestation for immunoglobulin A deficiency : a systematic review and meta-analysis
© 2023. Canadian Society of Allergy & Clinical Immunology..
OBJECTIVES: Immunoglobulin A deficiency (IgAD) is a common disease with an unknown genetic defect, characterized by the decreased or absent IgA with other isotypes normal, normal subclasses, and specific antibodies. Patients with this disorder represent a spectrum of clinical manifestations including infections, autoimmune disorders, malignancy, and allergic diseases. The current study aimed to evaluate their prevalence and categorized them.
METHODS: We searched PubMed, Web of Science, and Scopus databases to find eligible studies from the earliest available date to January 2022 with standard keywords. Pooled estimates of clinical manifestations prevalence and the corresponding 95% confidence intervals were calculated using random-effects models.
RESULTS: The most prevalent clinical manifestations belonged to infection (64.8%) followed by allergic diseases (26.16%) and autoimmunity (22.0%), respectively. In selective IgA deficiency patients as the largest group of IgAD in current study, celiac disease (6.57%), Inflammatory bowel disease (4.01%), and rheumatoid arthritis (3.80%) were the most prevalent autoimmunity. Meanwhile, the most frequent infection was respiratory tract infection, fungal infection, and gastrointestinal infection at 50.74%, 18.48%, and 15.79%, respectively. In addition, the pooled prevalence of asthma, allergic rhinitis, and allergic conjunctivitis were 19.06%, 15.46%, and 11.68%, respectively which were reported as the most widespread allergic diseases.
CONCLUSIONS: Our results showed that apart from undiagnosed IgAD patients, IgAD patients represent a wide range of clinical manifestations. Infection, allergy, and autoimmunity are the most common clinical manifestations. The concurrent presence of IgA and IgG subtypes deficiency could be associated with increased susceptibility to infection. Considering the probability of developing new clinical complications during follow-up, periodic assessments of IgAD patients should be inspected.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology - 19(2023), 1 vom: 28. Aug., Seite 75 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vosughimotlagh, Ahmad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allergic diseases |
|---|
| Anmerkungen: |
Date Revised 18.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s13223-023-00826-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361391390 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361391390 | ||
| 003 | DE-627 | ||
| 005 | 20231226085035.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13223-023-00826-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361391390 | ||
| 035 | |a (NLM)37641141 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vosughimotlagh, Ahmad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical manifestation for immunoglobulin A deficiency |b a systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 18.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023. Canadian Society of Allergy & Clinical Immunology. | ||
| 520 | |a OBJECTIVES: Immunoglobulin A deficiency (IgAD) is a common disease with an unknown genetic defect, characterized by the decreased or absent IgA with other isotypes normal, normal subclasses, and specific antibodies. Patients with this disorder represent a spectrum of clinical manifestations including infections, autoimmune disorders, malignancy, and allergic diseases. The current study aimed to evaluate their prevalence and categorized them | ||
| 520 | |a METHODS: We searched PubMed, Web of Science, and Scopus databases to find eligible studies from the earliest available date to January 2022 with standard keywords. Pooled estimates of clinical manifestations prevalence and the corresponding 95% confidence intervals were calculated using random-effects models | ||
| 520 | |a RESULTS: The most prevalent clinical manifestations belonged to infection (64.8%) followed by allergic diseases (26.16%) and autoimmunity (22.0%), respectively. In selective IgA deficiency patients as the largest group of IgAD in current study, celiac disease (6.57%), Inflammatory bowel disease (4.01%), and rheumatoid arthritis (3.80%) were the most prevalent autoimmunity. Meanwhile, the most frequent infection was respiratory tract infection, fungal infection, and gastrointestinal infection at 50.74%, 18.48%, and 15.79%, respectively. In addition, the pooled prevalence of asthma, allergic rhinitis, and allergic conjunctivitis were 19.06%, 15.46%, and 11.68%, respectively which were reported as the most widespread allergic diseases | ||
| 520 | |a CONCLUSIONS: Our results showed that apart from undiagnosed IgAD patients, IgAD patients represent a wide range of clinical manifestations. Infection, allergy, and autoimmunity are the most common clinical manifestations. The concurrent presence of IgA and IgG subtypes deficiency could be associated with increased susceptibility to infection. Considering the probability of developing new clinical complications during follow-up, periodic assessments of IgAD patients should be inspected | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Allergic diseases | |
| 650 | 4 | |a Autoimmune disorders | |
| 650 | 4 | |a Immunoglobulin A deficiency | |
| 650 | 4 | |a Infections | |
| 650 | 4 | |a Malignancy | |
| 700 | 1 | |a Rasouli, Seyed Erfan |e verfasserin |4 aut | |
| 700 | 1 | |a Rafiemanesh, Hosein |e verfasserin |4 aut | |
| 700 | 1 | |a Safarirad, Molood |e verfasserin |4 aut | |
| 700 | 1 | |a Sharifinejad, Niusha |e verfasserin |4 aut | |
| 700 | 1 | |a Madanipour, Atossa |e verfasserin |4 aut | |
| 700 | 1 | |a Dos Santos Vilela, Maria Marluce |e verfasserin |4 aut | |
| 700 | 1 | |a Heropolitańska-Pliszka, Edyta |e verfasserin |4 aut | |
| 700 | 1 | |a Azizi, Gholamreza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology |d 2005 |g 19(2023), 1 vom: 28. Aug., Seite 75 |w (DE-627)NLM193134780 |x 1710-1484 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:1 |g day:28 |g month:08 |g pages:75 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13223-023-00826-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 1 |b 28 |c 08 |h 75 | ||